Otsuka, Shape Ink Potential $1.5B Deal to Develop Eye AAV Gene Therapies

Otsuka, Shape Ink Potential $1.5B Deal to Develop Eye AAV Gene Therapies

Submitted by admin on September 8, 2023 - 10:11am
Source: 
BioSpace
News Tags: 
Otsuka
Shape Therapeutics
gene therapy
AAV gene therapy
RNA editing
ocular diseases
Headline: 
Otsuka, Shape Ink Potential $1.5B Deal to Develop Eye AAV Gene Therapies
snippet: 

Japan’s Otsuka Pharmaceuticals on Thursday announced a multi-target collaboration with RNA editing biotech Shape Therapeutics to develop intravitreal adeno-associated virus gene therapies for ocular diseases.

Do Not Allow Advertisers to Use My Personal information